| Popis: |
Background: Major depressive disorder (MDD) is a public health problem covering the world. According to the World Health Organization (WHO), more than 300 million people around the world suffer from MDD, which can cause huge social and economic losses.Medical therapy is the main treatment for MDD. However, antidepressants often have delayed efficacy and many side effects, which seriously affect the quality of life of patients.To systematically evaluate the efficacy and safety of Wuling capsule combined with antidepressant drug in the treatment of patients with MDD. Methods: Relevant documents published before December 1st, 2022 were retrieved from CNKI, WANFANG DATA, SinoMed, VJIP, CBM, Web of Science, Pubmed, Embase, PsycINFO, ICTRP, and Clinical Tra databases. Randomized controlled trials (RCTs) that meet the inclusion criteria were selected. Their qualities were evaluated and classified. The meta-analysis was performed using RevMan 5.4, and heterogeneity test and publication bias evaluation were performed. Results: This review includes 1835 patients from 19 RCT studies. The research takes the intervention mode as the variable. The results show that compared with using antidepressant drug alone, using Wuling capsule combined with antidepressant drug displays statistical significance in MDD patients’ Hamilton Depression Scale score (HAMD) [mean difference (MD)=-3.86, 95%CI (-4.05, -3.67), PConclusions: Compared with antidepressants alone, the Wuling capsule has an advantage in improving the HAMD score of patients with MDD, and the side effects are significantly less than those of the control group. Through this study, we believe that the Wuling capsule can be used as a safe and effective adjunctive drug for the treatment of patients with MDD. However, the quality of the evidence still needs to be further improved, and more high-quality clinical trials are needed to increase the credibility of the evidence. |
